Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302487 | 0.97 | ACACB (0.43) | ACACBHPGDATMMAP4K4 | |
| SCHEMBL13302478 | 0.94 | ACACB (0.45) | ACACBHPGDATMMAP4K4 | |
| SCHEMBL17049463 | 0.92 | ACACB (0.53) | ACACBHPGDATM | |
| SCHEMBL17977249 | 0.88 | PIN1 (0.44) | ACACB | |
| SCHEMBL2623651 | 0.88 | ACACB (0.46) | ACACBHPGDATMMAP4K4 | |
| SCHEMBL16800060 | 0.87 | ACACB (0.40) | ACACB | |
| SCHEMBL16800061 | 0.87 | ACACB (0.40) | ACACB | |
| SCHEMBL16800001 | 0.87 | ALDH1A1 (0.41) | ACACBHPGD | |
| SCHEMBL16799682 | 0.87 | ALDH1A1 (0.41) | ACACBHPGD | |
| SCHEMBL16799681 | 0.87 | ALDH1A1 (0.41) | ACACBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945619-B1 | CRYSTALLINE FORM OF VSN16 | UCL BUSINESS PLC (GB) | 2019-05-08 | — | — | EP | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9682924-B2 | Crystalline form of VSN16 | CANBEX THERAPEUTICS LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-9682924-B2 | Crystalline form of VSN16 | CANBEX THERAPEUTICS LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20150353476-A1 | CRYSTALLINE FORM OF VSN16 | ULC BUSINESS PLC (GB) | 2015-12-10 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010116116-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2010-10-14 | — | — | WO | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | ACACB 3036/4885HPGD 2698/4885ATM 4322/4885 |
| US-20150353476-A1 | CRYSTALLINE FORM OF VSN16 | VAC14, SFXN1, VIL1 | ACACB 2951/4885HPGD 3150/4885ATM 4857/4885 |
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | ACACB 3390/4885HPGD 1896/4885ATM 4443/4885 |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | CPT1B, MUSK, C1R | ACACB 208/4885HPGD 2246/4885ATM 3139/4885 |
| US-20100144876-A1 | MODULATOR | CHRNA3, CHRM3, NR3C2 | ACACB 3036/4885HPGD 2698/4885ATM 4322/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | ACACB 3843/4885HPGD 2385/4885ATM 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.